AstraZeneca Settles Generic Seroquel XR Row With Lupin

Law360, Chicago (April 11, 2013, 6:28 PM EDT) -- AstraZeneca Pharmaceuticals LP settled its New Jersey patent infringement suit against Lupin Ltd. on Thursday, striking a deal in which Lupin agreed not to make or sell a generic version of AstraZeneca's extended-release schizophrenia drug Seroquel XR before November 2016.

U.S. District Judge Joel A. Pisano signed off on the companies' consent judgment, in which Lupin also admitted that AstraZeneca's U.S. Patent Number 5,948,437 was enforceable and valid. The deal enjoins Lupin and its affiliates from dealing in a generic version of the drug in the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.